| Blue Elephant Counseling Llc | |
|
622 Liberty Rd Dannebrog NE 68831-3163 | |
| (308) 370-2580 | |
| Not Available |
| Full Name | Blue Elephant Counseling Llc |
|---|---|
| Speciality | Counselor |
| Location | 622 Liberty Rd, Dannebrog, Nebraska |
| Authorized Official Name and Position | Katherine Donahoo (OWNER) |
| Authorized Official Contact | 3083702580 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Blue Elephant Counseling Llc 622 Liberty Rd Dannebrog NE 68831-3163 Ph: (308) 370-2580 | Blue Elephant Counseling Llc 622 Liberty Rd Dannebrog NE 68831-3163 Ph: (308) 370-2580 |
| NPI Number | 1881353985 |
|---|---|
| Provider Enumeration Date | 12/16/2021 |
| Last Update Date | 11/18/2023 |
| Certification Date | 11/18/2023 |
| Medicare PECOS PAC ID | 3173976891 |
|---|---|
| Medicare Enrollment ID | O20240130001549 |
News Archive
America continues to lag behind other nations when it comes to gains in life expectancy, and commonly cited causes for our poor performance-obesity, smoking, traffic fatalities and homicide-are not to blame, according to a study by researchers at Columbia University's Mailman School of Public Health.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.
According to researchers, a drug used to treat patients with osteoporosis may soon be helpful in treating baldness. The study was published in the latest issue of the journal PLOS Biology this week.
MEDNAX, Inc. today reported earnings per share of $1.04 for the three months ended June 30, 2010, that were driven by contributions resulting from the Company's acquisitions and ongoing operating efficiencies.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881353985 | NPI | - | NPPES |
| 10026905100 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Secondary |
| Provider Name | Katherine Elizabeth Donahoo |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1376108076 PECOS PAC ID: 7416300140 Enrollment ID: I20240130001734 |
News Archive
America continues to lag behind other nations when it comes to gains in life expectancy, and commonly cited causes for our poor performance-obesity, smoking, traffic fatalities and homicide-are not to blame, according to a study by researchers at Columbia University's Mailman School of Public Health.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.
According to researchers, a drug used to treat patients with osteoporosis may soon be helpful in treating baldness. The study was published in the latest issue of the journal PLOS Biology this week.
MEDNAX, Inc. today reported earnings per share of $1.04 for the three months ended June 30, 2010, that were driven by contributions resulting from the Company's acquisitions and ongoing operating efficiencies.
› Verified 7 days ago
News Archive
America continues to lag behind other nations when it comes to gains in life expectancy, and commonly cited causes for our poor performance-obesity, smoking, traffic fatalities and homicide-are not to blame, according to a study by researchers at Columbia University's Mailman School of Public Health.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.
According to researchers, a drug used to treat patients with osteoporosis may soon be helpful in treating baldness. The study was published in the latest issue of the journal PLOS Biology this week.
MEDNAX, Inc. today reported earnings per share of $1.04 for the three months ended June 30, 2010, that were driven by contributions resulting from the Company's acquisitions and ongoing operating efficiencies.
› Verified 7 days ago